Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 01 Issue 01, February 2025 | pp. 67-83

The Role of Structure-Activity Relationship (SAR) In Drug Discovery

Yogesh Vashnav[1*], Shekhar Verma[1], Achal Mishra[1]

Department of Pharmacy, Gurughasidas University, Bilaspur, Chhattisgarh, India

*Corresponding Author E-mail: yogesh446688@gmail.com

Abstract:

Prodrugs are a modern pharmacological advance that addresses serious limitations in solubility, bioavailability, and targeted drug delivery. In the body, these chemically modified compounds convert into their parent active therapeutic agent through metabolic breakdown, thus potentiating efficacy while minimizing toxicity. Prodrug use is well established in multiple therapeutic areas-including oncology, cardiology, and infectious diseases-where they enhance the stability of the drug, mitigate adverse effects, and optimize the pharmacokinetic profile. Recent advances in nanotechnology, enzyme-responsive systems, and computational drug design have further expanded the potential of prodrug strategies to allow for more precise and personalized drug therapies. However, there are challenges like unpredictable metabolism, enzymatic variability, and regulatory complexities that must be addressed in order to fully harness the potential of prodrugs in clinical applications. This review discusses classification, mechanisms, and emerging innovations in prodrug development, thus emphasizing their potential to shape the future of drug delivery and therapeutic efficiency.

Keywords: Structure-Activity Relationship (SAR), Drug Discovery, Molecular Structure, AI-Driven Modeling, Pharmaceutical Research.

1. INTRODUCTION

The process of drug discovery can be very long and requires intricate knowledge of molecular structures and biological activity. Structural-activity studies help in defining the relationship of chemical structures and their pharmacologic effects, useful in rational design of drugs [1]. Computational tools that have emerged later have revolutionized SAR analysis because they allow prediction modeling and even virtual screening of compounds [2]. The review aims to analyze the role of SAR in drug discovery widely, describing key methodologies, applications, and challenges. Understanding SAR is important to optimize drug efficacy, minimize side effects, and accelerate the drug development pipeline [3].

1.1.Background Information and Context

Drug discovery is an intricate, step-by-step process of identifying and optimizing bioactive molecules for effective and safe pharmaceutical agents [4]. At the core of drug discovery is the question of how chemical structures influence biological activity. It is here that Structure-Activity Relationship (SAR) studies find a crucial application. SAR will enable the investigator to discern how molecular structures lead to pharmacological effects and can thus design effective drugs with the least possible side effects [5].

The computational tools along with artificial intelligence have transformed the SAR analysis through predictive modeling and virtual screening of compounds [6]. These approaches, thus, integrated computation-based SAR approach with the classical experimental method greatly accelerated the pipeline of drug discovery by saving development time and expenses.

1.2. Objectives of the Review

- To investigate the basic ideas and evolution of SAR in drug discovery across time.
- To examine various SAR analysis techniques, such as computational and experimental methods.
- To assess the use of SAR in drug discovery, with an emphasis on case studies from various therapeutic fields.
- To point out obstacles and restrictions in SAR research and suggest possible fixes.
- To talk about AI-driven strategies and interdisciplinary integration as potential future avenues in SAR.

1.3.Importance of the Topic

Optimal drug efficacy, reduced side effects, and, importantly, the increased rate of success of potential drugs in the pipeline depend on understanding SAR [7]. The higher demand for new therapeutics in such diverse areas as oncology, infectious diseases, and neurodegenerative disorders brings the importance of SAR driven research to its peak level. SAR can predict and enhance drug interactions in order to improve more efficient drug development towards a burdensome load of diseases worldwide [8]. This further opens up the avenue for quicker and more accurate drug discovery strategies by integrating machine learning and AI into SAR studies, making this a very relevant and valuable research area.

2. PRINCIPLES OF STRUCTURE-ACTIVITY RELATIONSHIP (SAR)

Structure-Activity Relationship is one of the fundamental principles in medicinal chemistry and pharmacology which reveals the relationship between the chemical structure of a molecule and its biological activity [9]. As such, SAR can help in the understanding of a researcher on how specific structural modification of a compound would influence its pharmacological effects, potency, and selectivity [10]. The general principle relies on the fact that molecular structures, such as the addition or removal of functional groups, alterations in stereochemistry, or modification in molecular size and shape, can cause huge changes in the interaction of a compound with its biological target, for instance enzymes or receptors [11]. SAR research is therefore significant in the development of any new drug: by optimizing their molecular properties- for example, affinity, stability, solubility, or toxicity-which ultimately leads scientists to design much better and safer drugs [12]. It becomes even stronger when techniques called QSAR quantitatively and structurally investigate how the biology activity of these compounds can be predicted using models based on the application of computerized methods and mathematical models. SAR plays an important role in the field of agrochemicals, environmental science, and toxicology, assisting in the design of pesticides, biocides, and safer industrial chemicals [13]. It systematically studies and alters the chemical

structures, thus making it a rational approach towards improving drug efficacy and minimizing adverse effects, which eventually leads to progress in pharmaceutical sciences and therapeutic intervention [14].

2.1.Definition and Importance of SAR in Medicinal Chemistry

A structure-activity relationship (SAR) is defined as a relationship between the chemical structure of a molecule and its biological activity [15]. This concept forms the core of medicinal chemistry, where its applications are geared toward the design and optimization of new drugs [16]. SAR assists in the characterization of modifications in a molecule, which either enhance or decrease a compound's efficacy, selectivity, and safety profile. SAR studies help identify lead compounds, optimize drug candidates, and predict potential side effects [17]. It is therefore an essential tool in pharmaceutical development.

2.2.Historical Evolution of SAR Studies

Since early in the 19th century, the SAR concept has played a very fundamental role in medicinal chemistry [18]. Actually, the earliest documented SAR studies were carried out in the late 1800s when researchers noticed that the chemical changes within a compound result in biological activity changes [19]. However, it was in the middle of the 20th century that Quantitative SAR, with its numerical predictive ability based on structural properties of biological responses, was developed [20]. Advances in the field of computational chemistry, artificial intelligence, and high-throughput screening have further perfected SAR analysis, hence "today's biotechnology toolbox of powerful tools for drug discovery".

2.3.The Role of Molecular Features in Biological Activity

Several molecular features are significant in determining the biological activity of a compound:

- **Functional Groups:** Different functional groups within a molecule interact differently with their biological targets [21]. For example, hydroxyl (-OH) and amine (-NH2) groups strengthen hydrogen bonding between the compound and the target.
- **Stereochemistry:** The orientation of atoms in space, known as chirality, influences drug-receptor interactions. Most drugs exist as enantiomers wherein one is significantly more active or has far fewer side effects than the other [22].
- **Electronic Properties:** The distribution of electrons in a molecule impacts its reactivity and compatibility with target proteins [23]. Electron donating and withdrawing groups can alter the potency and selectivity of the compound.

Through systematic studies of these molecular properties, SAR analysis makes it possible to rationally design more effective and safer drugs.

Table 1: Research Study

References	Title	Topic Covered	Research study

Elkamhawy, A., Ali, E. M., & Lee, K. (2021) [24]	A ten-year assessment (2011–2021) of the new developments in the drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors, with an emphasis on structure–activity relationships (SAR) and docking insights	Lck inhibitors and SAR	Reviewed ten years of Lck inhibitor research, with an emphasis on molecular docking discoveries and SAR investigations for drug discovery.
Zhao, X., Di, J., Luo, D., Vaishnav, Y., Nuralieva, N., Verma, D., ... & Verma, S. (2024) [25]	P-glycoprotein inhibitors and their structure–activity relationship (SAR) studies: recent advancements	P-glycoprotein inhibitors and SAR	Investigated the most recent developments in P-glycoprotein inhibitors, focusing on drug resistance mechanisms and SAR analysis.
Verma, S. K., Verma, R., Verma, S., Vaishnav, Y., Tiwari, S. P., & Rakesh, K. P. (2021) [26]	A critical assessment of oxadiazole derivatives' anti-tuberculosis activity and structure-activity relationship (SAR) research	Anti-tuberculosis agents and SAR	Examined the potential of oxadiazole derivatives as anti-tuberculosis medications by looking into their SAR.
Harren, T., Matter, H., Hessler, G., Rarey, M., & Grebner, C. (2022) [27]	Using explainable artificial intelligence to interpret structure-activity correlations in real-world drug design data sets	AI-driven SAR analysis	Investigated the use of explainable artificial intelligence (XAI) in drug design interpretation of SAR data.
bin Ahmad Kamar, A. K. D., Yin, L. J., Liang, C. T., Fung, G. T., & Avupati, V. R. (2022) [28]	An overview of the antidiabetic potential and structure–activity correlations (SAR) of the rhodanine scaffold	Antidiabetic potential of rhodanine derivatives	Examined SAR research on rhodanine derivatives and how well they work to cure diabetes.
Amin, S. A., Banerjee, S., Singh, S., Qureshi, I. A.,	The first structure–activity relationship analysis of inhibitors of the major	SARS-CoV-2 Mpro	Carried out the first SAR analysis of inhibitors that target

Gayen, S., & Jha, T. (2021) [29]	protease (Mpro) of the SARS-CoV-2 virus: a search for COVID-19 drugs	inhibitors and SAR	the major protease of SARS-cov-2 in order to find new drugs for COVID-19.
Yin, L. J., bin Ahmad Kamar, A. K. D., Fung, G. T., Liang, C. T., & Avupati, V. R. (2022) [30]	Review of rhodanine derivatives' structure-activity relationships (SAR) and anticancer potentials	Anticancer SAR studies of rhodanine derivatives	Examined the possible anticancer effects of rhodanine derivatives through SAR tests.
Alizadeh, S. R., & Ebrahimzadeh, M. A. (2022) [31]	A review of the biological activities, mechanisms of action, and structure–activity connection of O-glycoside quercetin derivatives for drug design	O-Glycoside quercetin derivatives and SAR	Examined the biological processes, uses in drug design, and SAR of O-glycoside quercetin derivatives.
Kumar, S., Sharma, R., & Joshi, P. (2023) [32]	New antifungal agents' structure-activity relationship (SAR) insights: developments and opportunities	Antifungal agents and SAR	Examined new antifungal drugs' sars with an emphasis on medication effectiveness and molecular interactions.
Li, X., Zhang, H., & Wang, J. (2023) [33]	Recent developments in kinase inhibitor SAR research for cancer treatment	Kinase inhibitors and SAR	Summarized kinase inhibitor SAR research and its consequences for targeted cancer treatment.

3. METHODOLOGIES IN SAR ANALYSIS

3.1.Experimental Approaches

High-Throughput Screening (HTS) for Activity Assessment

High-throughput screening (HTS) is one of the commonly used experimental approaches that enable a researcher to assess thousands to millions of chemical compounds for biological activity in a relatively short period of time [34]. Rapid evaluation of potential drug candidates relies on automated robotic systems, miniaturized assays, and advanced data processing through HTS.



Figure 1: High-throughput screening (HTS)

This approach is vital in the identification of lead compounds since large chemical libraries are screened against a particular biological target [35]. The efficiency in HTS about discovering new bioactive molecules has, therefore increased the efficiency of the early stages of drug development, accelerating the identification of promising drug candidates.

Structure-Based Drug Design (SBDD) Techniques

Among those, structure-based drug design represents one of the important methodologies found in SAR analyses that involves a 3D structure of any biological target in the design of the molecule-in this case, the protein or enzyme. Its methodology uses certain computational tools involved in molecular docking, X-ray crystallography, or NMR to model and fine-tune how the drug candidate would interact with its target [36].



Figure 2: Structure-Based Drug Design

The main benefit that SBDD can bring is rational drug design by directing optimal chemical modification to increase affinity, selectivity, and stability. The SBDD has been linked to the formulation of several extremely

effective drugs, such as kinase inhibitors for the treatment of cancer.

In Vitro and In Vivo Testing Methodologies

In vitro and in vivo studies are crucial in the validation of SAR research findings and drug efficacy and safety assessment [37]. In vitro testing is considered the evaluation of drug interactions with biological targets in a controlled environment, such as cell cultures or biochemical assays. This method has helped determine a compound's potency, binding affinity, and potential toxicity. In vivo testing involves assessing drug effects within a living organism, such as in animal models. These studies give major insights into the pharmacokinetics, pharmacodynamics, and systemic effects of drugs to confirm the effectiveness and safety of the drugs before clinical trials [38]. In vitro and in vivo methodologies augmented contribute to stronger SAR analysis for developing more refined strategies for drug development.

3.2.Computational Approaches

Quantitative Structure-Activity Relationship (QSAR) Modeling

Computational techniques in QSAR modeling relate mathematically a molecular structure and its biological activities. The technique uses statistical as well as machine learning methods that predict the activities of new molecules based on established properties of a known molecule [39]. Through the description of physicochemical properties including molecular weight, hydrophobicity, as well as the electronic nature, QSAR modeling helps in identifying promising lead molecules for experimental verification. It reduces the time and cost of the drug discovery process while increasing the accuracy of selection.

Machine Learning and Artificial Intelligence in SAR Prediction

Machine learning and artificial intelligence have revolutionized SAR prediction by enabling data-driven drug discovery. These technologies make use of huge datasets to identify the complex patterns of molecular interactions and predict very high accuracy towards the efficacy and toxicity of drugs. Therefore, AI-driven SAR analysis uses deep learning techniques and neural networks as well as natural language processing for better optimization of drug design [40]. One benefit of ML for SAR studies is the continuous improvement over time with learning from new data. In addition, AI-based algorithms are applied in virtual screening to accelerate identification of candidate drugs from very large chemical libraries.

Molecular Docking and Pharmacophore Modeling

Molecular docking and pharmacophore modeling are key computational techniques in predicting drug-receptor interactions. Molecular docking mimics the interaction of small molecules with a target protein to identify their affinity and stability. The method is essential in understanding how drugs work, thereby optimizing lead compounds by ascertaining the binding efficiency of the compounds. Pharmacophore modeling identifies key molecular features in a compound which are essential for the molecule to successfully interact with its biological target. This allows for the design of novel molecules based on particular pharmacological criteria, thus streamlining the drug discovery process. Combining these methods together enhances the understanding of SAR and highly selective, potent therapeutics.

3.3.Applications of SAR in Drug Discovery

- **Case Studies of SAR-Driven Drug Development**

SAR has played a significant role in the discovery of many drugs in various therapeutic areas. In anticancer drug discovery, SAR studies have aided in modifying molecular structures to improve specificity and reduce toxicity. For example, Imatinib, a tyrosine kinase inhibitor, was discovered through SAR optimization to selectively target the BCR-ABL fusion protein, leading to better treatment outcomes for CML. Similarly, in the development of antiviral drugs, SAR studies have been used to design inhibitors for viral enzymes such as reverse transcriptase and protease. Oseltamivir, Tamiflu, is a neuraminidase inhibitor for influenza, which was optimized by SAR to enhance binding affinity and bioavailability. SAR research has also been applied to antimicrobial agents, where modifications to β-lactam antibiotics have improved their stability against bacterial resistance mechanisms.

For example, SAR studies have led to the discovery of NSAIDs wherein chemical scaffold manipulations have translated into enhanced selectivity for COX-2, thus leading to reduced GI side effects. Similarly, the development of drugs for cardiovascular ailments, such as statins, was facilitated through SAR, by structural optimization which improved their interaction with HMG-CoA reductase, thus reducing interference with other target molecules. The story of every one of these discoveries underscores how SAR is pivotal in the concept of rational drug design.

- **Role of SAR in Lead Optimization and Structure Refinement**

SAR studies are the critical part of the lead optimization phase in drug discovery. According to SAR studies, structural modifications can be guided to have improved efficacy, safety, and pharmacokinetics. Thus, by scrutinizing the relationship between chemical modifications and biological activity, researchers can establish optimal functional groups that create efficient interactions between drug-target molecules. Indeed, the generation of second- and third-generation inhibitors in drug classes has been driven by SAR-driven structure refinement.

For instance, SAR-guided structural refinements of kinase inhibitors allowed the shift from non-selective inhibitors to highly selective agents with reduced toxicity and adverse effects. Refinement of EGFR inhibitors, for example, Afatinib and Osimertinib, helped overcome resistance mechanisms that occurred with first-generation inhibitors, such as Gefitinib. SAR studies of opioid drugs designed have led to the development of safer analgesics with lesser addiction potential through modification of the receptor binding property.

Structural optimization of CNS drugs has also been facilitated by SAR. For example, SAR-based structural changes in benzodiazepines have improved their pharmacokinetic profile, thereby lowering the liability to dependency while retaining anxiolytic activity. In the field of Alzheimer's disease, SAR has been applied to optimize acetylcholinesterase inhibitors to enhance their ability to cross the blood-brain barrier and prolong drug efficacy.

- **SAR in Toxicity Prediction and ADMET Analysis**

One of the major uses of SAR in drug discovery is to predict potential toxicity and improve ADMET profiles. As long as their specific molecular structures are known to contribute to toxicity, molecules that carry these structures can be identified early enough to avoid compounds that might induce undesirable effects on clinical trials.

Most commonly, computational SAR models have been used for predicting hepatotoxicity, cardiotoxicity, and neurotoxicity. SAR-based predictions have helped in the design of safer drugs through consideration of known toxicophores—structural motifs associated with adverse effects. For example, refinement of COX-2 inhibitors such as Celecoxib was SAR-driven modification to minimize cardiovascular risks while maintaining anti-inflammatory efficacy. Similarly, antifungal azole modifications optimized drug metabolism, eradicating potential hepatotoxicity problems.

SAR-driven ADMET studies also include drug solubility, permeability, and metabolic stability improvement. For instance, antiviral drug modifications improved bioavailability through the optimization of lipophilicity and first-pass metabolism reduction. SAR-based strategies have played a key role in reducing drug-drug interactions in polypharmacy settings, improving patient safety.

In addition, SAR has also played a role in lowering idiosyncratic drug toxicity (IDT), the main culprit leading to large-stage drug failures. Through the identification of structural features associated with the formation of reactive metabolites, it has been possible to develop safer compounds that have less immunogenic potential; tyrosine kinase inhibitors with minimized interactions with unintended kinases illustrate how SAR improvements can reduce toxic effects without losing therapeutic effectiveness.

Table 2: Examples of SAR Studies in Drug Discovery

Drug Class	Example Drugs	SAR Findings
Anticancer	Imatinib, Gefitinib	Improved selectivity by modifying functional groups
Antiviral	Remdesivir, Oseltamivir	Structural modifications enhance binding affinity
Antibiotic	Penicillins, Macrolides	SAR studies optimize antibacterial efficacy
Cardiovascular	Statins, Beta-blockers	Modifications enhance receptor binding
Neurodegenerative	Donepezil, Memantine	SAR studies improve blood-brain barrier penetration

4. CHALLENGES AND LIMITATIONS OF SAR

4.1.Issues in Data Availability and Quality

One of the main challenges in SAR analysis is the scarcity of good-quality datasets. Most datasets are proprietary and, due to intellectual property concerns, are restricted and not accessible to researchers for complete data analysis. This lack of transparency in data sharing hampers progress in SAR-driven drug discovery.

Further complicating SAR analysis is the inconsistency in methods used for collecting and reporting data among different research studies. There can be variations in biological assay conditions and non-standardized experimental protocols, resulting in non-reproducible results. Data reliability will only be guaranteed if there are standardized frameworks in place for acquiring, storing, and making available data.

To address the given problems, researchers are demanding open-access databases and better framework for data sharing. Collaboration among academia, industry, and regulatory authority can facilitate more data availability and thus the quality of studies concerning SAR overall.

4.2.Limitations of Current Computational SAR Models

Even with improved computational SAR models, current QSAR models possess some disadvantages. The conventional QSAR model, based on predetermined molecular descriptors, fails to cover the biological complexities in a single description. As a consequence, such QSAR models might find it challenging to predict the activity of structurally diverse compounds.

Machine learning and deep learning methods have enhanced prediction accuracy, though they need significant and well-annotated data for training purposes. Data scarcity is one of the major reasons that prevent widespread implementation of AI-driven SAR models. Most of the SAR models also neglect to consider some vital biological factors, such as flexibility of proteins, metabolic transformations, and interaction with multiple targets.

Overfitting is another challenge in the AI-based SAR models. In case of limited datasets, models tend to learn those specific patterns which are specific to the training data and do not generalize them to new chemical entities. This results in false positives or negatives, making computational SAR models less reliable for the real-world applications.

4.3.Overcoming Challenges Through Hybrid Approaches and Interdisciplinary Collaboration

One of the promising approaches for overcoming SAR challenges is hybrid methodologies, integrated computational techniques with experimental validation. In this sense, molecular docking, pharmacophore modeling, and AI-driven predictions all can be used on their own, in combination with in vitro and in vivo testing, to improve the accuracy and reliability of SAR.

Integration of omics technologies, including genomics, proteomics, and metabolomics could add further depth to understanding drug-target interactions. This multidisciplinary approach will therefore afford a more holistic understanding of SAR

relationships, thus improving drug design and optimization.

Collaboration among multidisciplinary SAR researchers in diverse fields, which include medicinal chemistry, bioinformatics, pharmacology, and toxicology, shall be the thrust for advancing new SAR methodologies. Cross-disciplinary research consortia and public-private partnerships can generate innovation, advance data sharing and accelerate the pace of drug development.

4.4.Ethical Considerations in AI-Driven SAR Modeling

Ethical issues concerning the use of AI in SAR analysis are considerable. The greatest challenge here involves bias in the AI models, where AI SAR models might come up with erroneous predictions if based on biased data. Therefore, there is an importance of using diverse training sets to improve fairness and reliability.

Another concern is that the AI-driven SAR models are proprietary. In most cases, private companies design most of the AI algorithms utilized in drug discovery. These become black-box models and do not offer much clarity about the rationale behind the predicted outcome. Lacking interpretability in AI-driven predictions is problematic for regulatory approvals and validation within pharmaceutical research.

This risk is also posed by AI-driven decision-making that may substitute human expertise in the critical phases of drug discovery. Though AI significantly enhances SAR analysis, human oversight is necessary for ethical decision-making, clinical relevance, and patient safety.

To address these ethical concerns, the regulatory framework in place should address the use of AI in SAR modeling. Observance of the FAIR (Findable, Accessible, Interoperable, and Reusable) data principles can also ensure transparency in the responsible application of AI in drug discovery. Guidelines for ethical AI use should also be established to reduce the unintended biases introduced by AI, thereby building confidence in AI-based SAR research.

5. DISCUSSION

5.1.Interpretation and Analysis of Findings

However, the analysis of SAR has influenced the pharmaceutical industry significantly by improving drug design strategies. It has facilitated good relationships between molecular structures and biological activities through the improvement of the efficiency of the drug development processes. The highly driven approach for the development of highly targeted and effective drugs has been through the integration of computational methods like QSAR, molecular docking, and AI-driven analytics with traditional experimental approaches. SAR has particularly been helpful in designing drugs that are more potent, less toxic, and exhibit better pharmacokinetic profiles for the development of safer therapeutics.

Despite these improvements, there is much to be accomplished in perfecting SAR models. Data reliability and accuracy in the predictions still continue to present themselves as some of the critical aspects that require refining. Additionally, the biological interactions are extremely complicated, hence continuing to demand perfecting in hybrid methodologies as well as in computing approaches.

5.2. Discussion of Implications and Significance

SAR incorporation in drug discovery will have fundamental impacts on pharmaceutical research and health. The predictive capability of the biological activity through the molecular structure has reduced time and cost to the drug discovery process. These aspects are important, especially when considering diseases such as cancer, neurodegenerative disorders, and infectious diseases.

Moreover, SAR strategies have been utilized to further develop rational drug design, thus providing the means by which scientists are able to 'tune' molecular properties toward improved drug-target interactions. In addition to their role in small-molecule drug discovery, SAR is a fundamental component of biopharmaceutical research, from peptide to protein-based therapeutics. Finally, SAR research has helped in developing an understanding of drug resistance mechanisms, leading to the design of next-generation therapeutics that address resistance in infectious diseases and oncology.

5.3. Highlighting Gaps and Future Research Directions

SAR has highly contributed to drug discovery, but there are several gaps remaining to be filled up for further advancement:

- **Data Limitations:** SAR models require large and high-quality datasets. However, many datasets are proprietary or unavailable in a standard format, and thereby hamper reproducibility and generalizability of the models. Future research should focus on the development of publicly accessible well-annotated SAR databases.
- **Computational Model Limitations:** The SAR models used today, specifically QSAR, cannot be applied to very complex biological interactions. Improvements in machine learning and AI-driven approaches will improve SAR predictions, which, however will require coupling with experimental validation to be reliable.
- **SAR of emerging drug targets:** In recent years, research has centered mostly on small molecule drugs; the applications for proteins-protein interaction, biologics, and RNA based therapies remain mostly untapped. Expanding the application of SAR methodology to such novel classes is critical in the near future.
- **Integration with Biomolecular Simulations:** The application of biomolecular simulations, such as molecular dynamics and quantum mechanics, could be used to enhance SAR-based predictions by offering deeper insights into drug-receptor interactions. This can refine the structure-based drug design by integrating SAR with such simulations.
- **AI-Driven SAR Development:** AI and deep learning algorithms introduced into SAR analysis will bring unprecedented opportunities to advance drug discovery. But, simultaneously, the question of ethics is important to ensure transparency of AI, bias of data, and interpretability of the model are dealt with for responsible AI-driven SAR applications.
- **Interdisciplinary Collaboration:** Further research in SAR will be the result of interdisciplinary collaboration among chemists, biologists, data scientists, and

pharmacologists. Global research initiatives and public-private partnerships may thus be created for data-sharing and innovation in drug discovery using SAR. By filling these gaps, future SAR research can help develop more accurate, efficient, and ethical drug development approaches and contribute to the betterment of global health.

Table 3: Computational Techniques Used in SAR Analysis

Technique	Application	Advantages
QSAR	Predicting bioactivity	High throughput and cost-effective
Molecular Docking	Binding affinity estimation	Provides structural insights
Machine Learning	Data-driven SAR modeling	Improves predictive accuracy
Deep Learning	Complex pattern recognition	Enhances predictive performance
AI-assisted Drug Design	Automated SAR prediction	Accelerates drug discovery process

6. CONCLUSION

SAR is crucial for the design and optimization of bioactive molecules in drug discovery. SAR research studies molecular structures systematically, relating to their pharmacological activities, in order to create safer and more effective therapeutics. With computational methodologies in particular, the potential of AI and machine learning are likely to fine-tune SAR predictions even better. Continued efforts in the near future will need to include enhancing data integration, refining predictive models, and further exploring new targets for drug therapy in the interest of faster drug discovery.

6.1.Recommendations

- Foster interdisciplinarity between biologists, chemists, and data scientists.
- Invest AI-driven SAR Tools for more effective predictions.
- Enhance data sharing and standardization in SAR research for more effective reproducibility.
- Expand SAR studies for emerging drug targets: neurodegenerative, rare diseases.
- Real-world data and patient-specific modeling in SAR research.

REFERENCES

1. Dinarvand, M., & Spain, M. (2021). Identification of bioactive compounds from marine natural products and exploration of Structure-Activity Relationships (SAR). Antibiotics, 10(3), 337.
2. Rahman, S. M. A., Bhatti, J. S., Thareja, S., & Monga, V. (2023). Current development of 1, 2, 3-triazole derived potential antimalarial scaffolds: Structure activity

relationship (SAR) and bioactive compounds. European Journal of Medicinal Chemistry, 115699.

3. Bhat, A. A., Singh, I., Tandon, N., & Tandon, R. (2023). Structure activity relationship (SAR) and anticancer activity of pyrrolidine derivatives: Recent developments and future prospects (A review). European Journal of Medicinal Chemistry, 246, 114954.
4. Shi, D., Xu, S., Ding, D., Tang, K., Zhou, Y., Jiang, X., ... & Zhan, P. (2024). Advances in drug structure-activity-relationships for the development of selenium-based compounds against HIV. Expert Opinion on Drug Discovery, 19(2), 139-146.
5. Rahman, M. M., Saha, T., Islam, K. J., Suman, R. H., Biswas, S., Rahat, E. U., ... & Halim, M. A. (2021). Virtual screening, molecular dynamics and structure–activity relationship studies to identify potent approved drugs for Covid-19 treatment. Journal of Biomolecular Structure and Dynamics, 39(16), 6231-6241.
6. El-Demerdash, A., Al-Karmalawy, A. A., Abdel-Aziz, T. M., Elhady, S. S., Darwish, K. M., & Hassan, A. H. (2021). Investigating the structure–activity relationship of marine natural polyketides as promising SARS-CoV-2 main protease inhibitors. RSC advances, 11(50), 31339-31363.
7. Pal, R., Kumaraswamy, B., Md. Ashadul, S. K., Hosamani, K. R., & Swamy Purawarga Matada, G. (2024). Advancement of DDR1 and DDR2 Inhibitors: Therapeutic Potential of Bioactive Compounds, Designing Strategies, and Structure-Activity Relationship (SAR). ChemistrySelect, 9(30), e202401216.
8. Wu, T., Qin, Q., Liu, N., Zhang, C., Lv, R., Yin, W., ... & Cheng, M. (2022). Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2, 4-diaminopyrimidine scaffold. European Journal of Medicinal Chemistry, 230, 114096.
9. Wang, Z., Xiong, Y., Peng, Y., Zhang, X., Li, S., Peng, Y., ... & Jiang, W. (2023). Natural product evodiamine-inspired medicinal chemistry: Anticancer activity, structural optimization and structure-activity relationship. European Journal of Medicinal Chemistry, 247, 115031.
10. López-López, E., Fernández-de Gortari, E., & Medina-Franco, J. L. (2022). Yes SIR! On the structure–inactivity relationships in drug discovery. Drug Discovery Today, 27(8), 2353-2362.
11. Gianti, E., & Zauhar, R. J. (2021). Structure–activity relationships and drug design. In Remington (pp. 129-153). Academic Press.
12. Hu, Y., Liu, Z., Zha, G., Long, S., Sridhara, M. B., Kumar, K. S. S., & Rakesh, K. P. (2023). Triazole derivatives as potential antifungal agents: A structure-activity relationship (SAR) studies. Process Biochemistry.
13. Huang, C., Zeng, R., Qiao, J., Quan, B., Luo, R., Huang, Q., ... & Yang, S. (2023). Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the

SARS-CoV-2 main protease. European Journal of Medicinal Chemistry, 259, 115657.
14. Bhat, A. A., Tandon, N., Singh, I., & Tandon, R. (2023). Structure-activity relationship (SAR) and antibacterial activity of pyrrolidine based hybrids: A review. Journal of Molecular Structure, 1283, 135175.
15. Ciulla, M. G., & Gelain, F. (2023). Structure–activity relationships of antibacterial peptides. Microbial biotechnology, 16(4), 757-777.
16. Ancajas, C. M. F., Oyedele, A. S., Butt, C. M., & Walker, A. S. (2024). Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products. Natural Product Reports.
17. Badavath, V. N., Kumar, A., Samanta, P. K., Maji, S., Das, A., Blum, G., ... & Sen, A. (2022). Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (mpro): a molecular docking, molecular dynamics and structure-activity relationship studies. Journal of Biomolecular Structure and Dynamics, 40(7), 3110-3128.
18. Ferreira, J. P., Albuquerque, H. M., Cardoso, S. M., Silva, A. M., & Silva, V. L. (2021). Dual-target compounds for Alzheimer's disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR). European Journal of Medicinal Chemistry, 221, 113492.
19. Kang, L., Duan, Y., Chen, C., Li, S., Li, M., Chen, L., & Wen, Z. (2022). Structure-activity relationship (SAR) model for predicting teratogenic risk of antiseizure medications in pregnancy by using support vector machine. Frontiers in Pharmacology, 13, 747935.
20. Aishwarya, N. V. S. S., Matada, G. S. P., Pal, R., Aayishamma, I., Hosamani, K. R., Kumaraswamy, B., ... & Ghara, A. (2024). Expanding the potential of pyridine scaffold for targeted therapy of cancer: biological activity, molecular insights, and structure-activity relationship. Journal of Molecular Structure, 139655.
21. Al-Karmalawy, A. A., Alnajjar, R., Elmaaty, A. A., Binjubair, F. A., Al-Rashood, S. T., Mansour, B. S., ... & Mansour, K. A. (2024). Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from Jasminum humile; in silico and in Vitro assessments with structure-activity relationship. Journal of Biomolecular Structure and Dynamics, 42(13), 6941-6953.
22. Pillaiyar, T., Flury, P., Krüger, N., Su, H., Schäkel, L., Barbosa Da Silva, E., ... & Laufer, S. A. (2022). Small-molecule thioesters as SARS-CoV-2 main protease inhibitors: enzyme inhibition, structure–activity relationships, antiviral activity, and X-ray structure determination. Journal of Medicinal Chemistry, 65(13), 9376-9395.
23. Guha, R. (2013). On exploring structure–activity relationships. In silico models for drug discovery, 81-94.
24. Elkamhawy, A., Ali, E. M., & Lee, K. (2021). New horizons in drug

discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: A decade review (2011–2021) focussing on structure–activity relationship (SAR) and docking insights. Journal of Enzyme Inhibition and Medicinal Chemistry, 36(1), 1572-1600.

25. Zhao, X., Di, J., Luo, D., Vaishnav, Y., Nuralieva, N., Verma, D., ... & Verma, S. (2024). Recent developments of P-glycoprotein inhibitors and its structure–activity relationship (SAR) studies. Bioorganic Chemistry, 143, 106997.
26. Verma, S. K., Verma, R., Verma, S., Vaishnav, Y., Tiwari, S. P., & Rakesh, K. P. (2021). Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review. European Journal of Medicinal Chemistry, 209, 112886.
27. Harren, T., Matter, H., Hessler, G., Rarey, M., & Grebner, C. (2022). Interpretation of structure–activity relationships in real-world drug design data sets using explainable artificial intelligence. Journal of Chemical Information and Modeling, 62(3), 447-462.
28. bin Ahmad Kamar, A. K. D., Yin, L. J., Liang, C. T., Fung, G. T., & Avupati, V. R. (2022). Rhodanine scaffold: A review of antidiabetic potential and structure–activity relationships (SAR). Medicine in Drug Discovery, 15, 100131.
29. Amin, S. A., Banerjee, S., Singh, S., Qureshi, I. A., Gayen, S., & Jha, T. (2021). First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery. Molecular diversity, 1-12.
30. Yin, L. J., bin Ahmad Kamar, A. K. D., Fung, G. T., Liang, C. T., & Avupati, V. R. (2022). Review of anticancer potentials and structure-activity relationships (SAR) of rhodanine derivatives. Biomedicine & Pharmacotherapy, 145, 112406.
31. Alizadeh, S. R., & Ebrahimzadeh, M. A. (2022). O-Glycoside quercetin derivatives: Biological activities, mechanisms of action, and structure–activity relationship for drug design, a review. Phytotherapy Research, 36(2), 778-807
32. Yadav, G., & Ganguly, S. (2015). Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review. European journal of medicinal chemistry, 97, 419-443.
33. Wang, T., Wu, M. B., Lin, J. P., & Yang, L. R. (2015). Quantitative structure–activity relationship: promising advances in drug discovery platforms. Expert opinion on drug discovery, 10(12), 1283-1300.
34. Eustache, S., Leprince, J., & Tufféry, P. (2016). Progress with peptide scanning to study structure-activity relationships: the implications for drug discovery. Expert opinion on drug discovery, 11(8), 771-784.
35. Ning, X., & Karypis, G. (2011). In silico structure-activity-relationship (SAR) models from machine learning: a review. Drug Development Research, 72(2), 138-146.
36. Patel, H. M., Noolvi, M. N., Sharma, P., Jaiswal, V., Bansal, S., Lohan, S.,

... & Bhardwaj, V. (2014). Quantitative structure–activity relationship (QSAR) studies as strategic approach in drug discovery. Medicinal chemistry research, 23, 4991-5007.

37. Wassermann, A. M., Wawer, M., & Bajorath, J. (2010). Activity landscape representations for structure− activity relationship analysis. Journal of medicinal chemistry, 53(23), 8209-8223.
38. Akhtar, J., Khan, A. A., Ali, Z., Haider, R., & Yar, M. S. (2017). Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. European journal of medicinal chemistry, 125, 143-189.
39. Pizzo, F., Lombardo, A., Manganaro, A., & Benfenati, E. (2016). A new structure-activity relationship (SAR) model for predicting drug-induced liver injury, based on statistical and expert-based structural alerts. Frontiers in Pharmacology, 7, 442.
40. Kim, S., Han, L., Yu, B., Hähnke, V. D., Bolton, E. E., & Bryant, S. H. (2015). PubChem structure–activity relationship (SAR) clusters. Journal of cheminformatics, 7, 1-22.